BIIB - Picture Perfect Market Maker ModelQuite Frankly This Is a Piece of Art.
Ai is been helping Bio Tech massively
Using the 3 Month and 1 Month Time frames we have a perfect Market maker model. Consolidation up top with market manipulation straight to distribution (A,M,D)
- 2 main accumulations before it hit's a perfect fair value g
775 ARS
1.49 T ARS
8.49 T ARS
About Biogen Inc.
Sector
Industry
CEO
Christopher A. Viehbacher
Website
Headquarters
Cambridge
Founded
1978
ISIN
ARBCOM4601A8
FIGI
BBG00PCCBPX0
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
No news here
Looks like there's nothing to report right now
BIIB is BullishPrice was in a strong downtrend, however a matured bullish divergence hints the return of bulls. If the descending trendline is broken with volume along with the previous lower high then according to Dow theory we can expect a bullish reversal. Targets are mentioned on the chart.
NLong

$BIIB imploding to the downsideStock is leaking out lows, next stop 182.23 where we should bounce. Until then i am #bearish
NShort

BIIB Long, Coming Soon!The price has sold off from the $207.59 pivot level, dropping to $193.84 as of the Monday, September 30th close. The sharp decline from $200 to $190 over two days last week was largely due to sector-wide weakness, as reflected in the IBB (Biotech ETF). Since then, both the ETF and BIIB have been con
NLong

BIIB - Breakout soonBIIB is forming a tight pennant setup. Either this gonna breakout here and rally or Fakeout and crash. Let’s see..!
Long anywhere here.
Target #1 - 250
Target #2 - 260
Target #3 - 275
Stop loss - 225
NLong

BIIB bear trend breakout? BIIB has broken a long running bearish trend since Jan 2023
Entry @ 223
TP1 @ 255
SL @ 200
Fundamentally strong stock hence the far off Stop loss but still a 1:2 ratio risk reward
NLong

Biogen Stock Surge 4.85% on Approval For ALS DrugBiogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical need
NLong

NLong

Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 cu
NLong

9 year consolidation about over?Might make this one a core position over the coming months... 200 month moving average tested successfully once already.
NLong

See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050Yield to maturity
7.78%
Maturity date
May 1, 2050
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
7.72%
Maturity date
Feb 15, 2051
US9062XAD5
BIOGEN INC. 15/45Yield to maturity
6.70%
Maturity date
Sep 15, 2045
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030Yield to maturity
5.34%
Maturity date
May 1, 2030
IDPC
BIOGEN INC. 15/25Yield to maturity
5.06%
Maturity date
Sep 15, 2025
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
4.65%
Maturity date
Feb 15, 2051
See all BIIB bonds
Curated watchlists where BIIB is featured.